Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
Recruiting
Phase 4
Interventional Study
Degenerative Heart Valve Disease
Heart Valve Calcification
Chronic Kidney Disease(CKD)
Calcium-Phosphorus Metabolism Disorders
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 50 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 196 (estimated)
- Sponsor
- China National Center for Cardiovascular Diseases · Government
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this clinical trial is to learn if calcium-phosphorus regulation therapy can slow the progression of heart valve calcification in patients with degenerative heart valve disease and chronic kidney disease (CKD). The main questions it aims to answer are:
* Does Sevelamer lower the progression of heart valve calcification compared to calcium carbonate over 12 months?
* What are the impac…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age ≥ 50 years old.
* Degenerative valvular heart disease clearly diagnosed by ultrasound or clinical history with calcification manifestation (including no stenosis or insufficiency due to calcification, mild, moderate and severe stenosis and insufficiency caused by calcif…
Contacts